journal article·2022-02-11Open access

Assessment of Dendrigrafts of Poly-l-lysine Cytotoxicity and Cell Penetration in Cancer Cells

Fabien Granier, Sébastien Marie, Zahra Al Amir Dache, Julien Aityaya, Thibault Mazard, Laurent Garrelly, Corinne Prévostel

ACS Applied Polymer Materials· Volume 4· Issue 2

Abstract

This work provides an in vitro methodology to assess the cytotoxicity and cell penetration of dendrigrafts of poly-l-lysine (DGLs) in order to select the best molecules to be further tested in preclinical models as nanoscale drug carriers for cancer treatment. The data obtained indicate that, despite their higher molecular weight, DGLs cause cytotoxicity close to that published for other dendrimers (half maximal inhibitory concentration (IC50) > 100 nM up to 1.5 μM depending on the DGL generation and the colon cancer cell line). Besides, the uptake of DGLs by cancer cells was observed within 5 min through a clathrin-dependent process. At a concentration at least 10-fold lower than the IC50 (10 nM), 60–80% of colon cancer cells internalized DGL-G3, -G4, and -G5 within 4 h, while a cell penetration efficiency of 20–60% was observed for DGL-G2. Finally, DGL cytotoxicity was significantly decreased by serum components. This methodology provides robust data to guide DGL functionalization to further reduce DGL cytotoxicity and safely address anticancer drugs to cancer cells and represents a standardized and easy-to-use approach to characterize nanovectors for biological applications.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Dendrimers and Hyperbranched Polymers · Biopolymer Synthesis and Applications · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

COLCOM, Cap Alpha, 3 Avenue de l’Europe, 34830 Clapiers, France

FGHI, Cap Alpha, 3 Avenue de l’Europe, 34830 Clapiers, France

Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), Campus Val d’Aurelle, 208 Avenue des Apothicaires, 34298 cedex 5 Montpellier, France

References (45)

Show source-provided references
1. 10.3109/1061186X.2015.105104910.3109/1061186X.2015.1051049 ↗
2. 10.2147/IJN.S16521010.2147/IJN.S165210 ↗
3. 10.1053/ctrv.2002.026210.1053/ctrv.2002.0262 ↗
4. 10.1063/1.507994310.1063/1.5079943 ↗
5. 10.1211/jpp.58.11.001010.1211/jpp.58.11.0010 ↗
6. 10.1038/ncomms872210.1038/ncomms8722 ↗
7. 10.1016/j.addr.2013.01.00110.1016/j.addr.2013.01.001 ↗
8. 10.1016/j.ijpharm.2018.07.03010.1016/j.ijpharm.2018.07.030 ↗
9. 10.1002/(SICI)1097-4636(199601)30:1<53::AID-JBM8>3.0.CO;2-Q10.1002/(SICI)1097-4636(199601)30:1<53::AID-JBM8>3.0.CO;2-Q ↗
10. 10.1055/s-1978-2470210.1055/s-1978-24702 ↗
11. 10.1295/polymj.17.11710.1295/polymj.17.117 ↗
12. 10.1016/j.ijpharm.2010.04.02710.1016/j.ijpharm.2010.04.027 ↗
13. 10.1021/ma300485p10.1021/ma300485p ↗
14. 10.1080/09205063.2014.93897910.1080/09205063.2014.938979 ↗
15. 10.1021/mp060032e10.1021/mp060032e ↗
16. https://www.starpharma.com.
17. Rupp R. · Int. J. Nanomedicine · 2007 · 2 · 561
18. https://clinicaltrials.gov.
19. http://www.colcom.eu.
20. 10.1002/chem.20090173410.1002/chem.200901734 ↗
21. Denkewalter, R. G.; Kolc, J. F.; Lukasavage, W. J. Preparation of Lysine Based Macromolecular Highly Branched Homogeneous Compound. US 4,360,646, 1979.
22. 10.1002/cbic.20070028910.1002/cbic.200700289 ↗
23. 10.1021/bm700668w10.1021/bm700668w ↗
24. 10.1016/j.ejps.2020.10569310.1016/j.ejps.2020.105693 ↗
25. 10.1002/chem.20170414710.1002/chem.201704147 ↗
26. 10.1002/cmdc.20080019010.1002/cmdc.200800190 ↗
27. 10.3390/biom908033010.3390/biom9080330 ↗
28. 10.18632/oncotarget.1057310.18632/oncotarget.10573 ↗
29. 10.1158/1535-7163.MCT-18-114910.1158/1535-7163.MCT-18-1149 ↗
30. 10.3390/cancers1105069310.3390/cancers11050693 ↗
31. 10.3168/jds.2016-1218610.3168/jds.2016-12186 ↗
32. 10.1016/j.jsb.2010.07.00210.1016/j.jsb.2010.07.002 ↗
33. 10.1021/mp500765e10.1021/mp500765e ↗
34. 10.1186/s12943-017-0691-y10.1186/s12943-017-0691-y ↗
35. 10.1021/bc049962b10.1021/bc049962b ↗
36. 10.1021/nl072292910.1021/nl0722929 ↗
37. 10.1093/nar/gkh59510.1093/nar/gkh595 ↗
38. 10.1016/j.jim.2006.06.00710.1016/j.jim.2006.06.007 ↗
39. https://app.biorender.com.
40. 10.1016/j.ijpharm.2005.10.03910.1016/j.ijpharm.2005.10.039 ↗
41. 10.1016/j.taap.2010.08.01610.1016/j.taap.2010.08.016 ↗
42. 10.1016/j.chroma.2014.12.02910.1016/j.chroma.2014.12.029 ↗
43. 10.1007/s12274-021-3616-410.1007/s12274-021-3616-4 ↗
44. 10.1002/EXP.2021000310.1002/EXP.20210003 ↗
45. 10.1002/EXP.2021015310.1002/EXP.20210153 ↗